

Ming-Fong Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8358422/publications.pdf>

Version: 2024-02-01

45
papers

1,543
citations

361296

20
h-index

302012

39
g-index

45
all docs

45
docs citations

45
times ranked

1911
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel pregnene analogs: synthesis, cytotoxicity on prostate cancer of PC-3 and LNCaP cells and in silico molecular docking study. <i>Molecular Diversity</i> , 2021, 25, 661-671.	2.1	5
2	Multifunctionality of Prostatic Acid Phosphatase in Prostate Cancer Pathogenesis. <i>Bioscience Reports</i> , 2021, , .	1.1	1
3	Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis. <i>Bioscience Reports</i> , 2021, 41, .	1.1	7
4	Targeting treatment options for castration-resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2021, 9, 101-120.	0.4	4
5	p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. <i>Free Radical Biology and Medicine</i> , 2019, 139, 24-34.	1.3	15
6	ErbB-2 signaling in advanced prostate cancer progression and potential therapy. <i>Endocrine-Related Cancer</i> , 2019, 26, R195-R209.	1.6	17
7	p66Shc regulates migration of castration-resistant prostate cancer cells. <i>Cellular Signalling</i> , 2018, 46, 1-14.	1.7	19
8	Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 436, 96-108.	3.2	7
9	Shifted Golgi targeting of glycosyltransferases and α -mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N-glycans in aggressive prostate cancer cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2891-2901.	1.1	18
10	Cyproterone acetate enhances TRAIL-induced androgen-independent prostate cancer cell apoptosis via up-regulation of death receptor 5. <i>BMC Cancer</i> , 2017, 17, 179.	1.1	10
11	Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells. <i>Journal of Oncology Research and Therapy</i> , 2017, 3, .	0.0	0
12	Statin derivatives as therapeutic agents for castration-resistant prostate cancer. <i>Cancer Letters</i> , 2016, 383, 94-105.	3.2	24
13	Cellular prostatic acid phosphatase (cPAP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. <i>Cell and Bioscience</i> , 2015, 5, 38.	2.1	5
14	Novel Imidazopyridine Derivatives Possess Anti-Tumor Effect on Human Castration-Resistant Prostate Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0131811.	1.1	23
15	Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. <i>Therapeutic Advances in Urology</i> , 2015, 7, 388-395.	0.9	50
16	ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. <i>Cellular Signalling</i> , 2015, 27, 2261-2271.	1.7	29
17	p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. <i>Molecular Carcinogenesis</i> , 2015, 54, 618-631.	1.3	12
18	Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer. <i>Oncotarget</i> , 2015, 6, 3887-3903.	0.8	37

#	ARTICLE	IF	CITATIONS
19	Discovery of Novel <i>N</i> -alkyl 4-anilino-furo[2,3- <i>b</i>]quinoline Derivatives (CIL-102 Derivatives) Against Castration-resistant Human Prostate Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 493-500.	0.9	4
20	Vitamin D3 Regulates the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e106437.	1.1	18
21	Antischistosomal versus Antiandrogenic Properties of Aryl Hydantoin Ro 13-3978. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 1156-1158.	0.6	8
22	Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 88-98.	3.3	21
23	Antiproliferative activity of novel imidazopyridine derivatives on castration-resistant human prostate cancer cells. <i>Cancer Letters</i> , 2014, 353, 59-67.	3.2	25
24	Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells. <i>Free Radical Biology and Medicine</i> , 2012, 53, 95-108.	1.3	28
25	Steroids Up-Regulate p66Shc Longevity Protein in Growth Regulation by Inhibiting Its Ubiquitination. <i>PLoS ONE</i> , 2011, 6, e15942.	1.1	17
26	5-azadeoxycytidine suppresses androgen independent prostate cancer growth by restoring RGS2 expression. <i>FASEB Journal</i> , 2011, 25, 802.6.	0.2	0
27	p66Shc is a longevity redox protein in human prostate cancer progression and metastasis. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 207-222.	2.7	45
28	Human Prostatic Acid Phosphatase, an Authentic Tyrosine Phosphatase, Dephosphorylates ErbB-2 and Regulates Prostate Cancer Cell Growth. <i>Journal of Biological Chemistry</i> , 2010, 285, 23598-23606.	1.6	45
29	A novel role of Shc adaptor proteins in steroid hormone-regulated cancers. <i>Endocrine-Related Cancer</i> , 2009, 16, 1-16.	1.6	33
30	Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. <i>Molecular and Cellular Endocrinology</i> , 2008, 295, 115-120.	1.6	191
31	Vasoactive intestinal peptide transactivates the androgen receptor through a PKA-dependent extracellular signal-regulated kinase pathway in prostate cancer cells. <i>FASEB Journal</i> , 2007, 21, .	0.2	0
32	Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. <i>Endocrine-Related Cancer</i> , 2006, 13, 151-167.	1.6	140
33	Regulator of G-protein Signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. <i>FASEB Journal</i> , 2006, 20, A1120.	0.2	0
34	Expression of p66Shc protein correlates with proliferation of human prostate cancer cells. <i>Oncogene</i> , 2005, 24, 7203-7212.	2.6	55
35	p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. <i>International Journal of Cancer</i> , 2004, 108, 672-678.	2.3	44
36	Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. <i>Oncogene</i> , 2003, 22, 6704-6716.	2.6	69

#	ARTICLE	IF	CITATIONS
37	Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. <i>Prostate</i> , 2002, 50, 222-235.	1.2	166
38	DECREASED EXPRESSION OF CELLULAR PROSTATIC ACID PHOSPHATASE INCREASES TUMORIGENICITY OF HUMAN PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 2001, 166, 1943-1950.	0.2	66
39	PROTEIN KINASE C PATHWAY IS INVOLVED IN REGULATING THE SECRETION OF PROSTATIC ACID PHOSPHATASE IN HUMAN PROSTATE CANCER CELLS. <i>Cell Biology International</i> , 2001, 25, 1139-1148.	1.4	9
40	Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. <i>Oncogene</i> , 2000, 19, 2664-2677.	2.6	66
41	Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines. <i>Molecular and Cellular Biochemistry</i> , 2000, 208, 11-18.	1.4	5
42	Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 1998, 273, 5939-5947.	1.6	122
43	Tyrosine Phosphorylation of c-ErbB-2 Is Regulated by the Cellular Form of Prostatic Acid Phosphatase in Human Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 22096-22104.	1.6	78
44	Pathological Processes Related to Redox. , 0, , 183-225.		0
45	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5